Abbvie to record $3.5 bln charge related to schizophrenia drug-February 2024-www.financetom.com

Abbvie to record $3.5 bln charge related to schizophrenia drug

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Abbvie to record $3.5 bln charge related to schizophrenia drug

Jan 10, 2025 6:04 AM

Jan 10 (Reuters) - Abbvie ( ABBV ) said on Friday it

will record a charge of about $3.5 billion related to its

experimental schizophrenia drug, emraclidine, which recently

failed in two mid-stage studies.

Previous page： HomeStreet Secures Shareholder Approval for Merger With FirstSun Next page： NeueHealth Gets NYSE Noncompliance Notice Over Market Cap Requirements

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

HomeStreet Secures Shareholder Approval for Merger With FirstSun

Jun 18, 2024

05:30 PM EDT, 06/18/2024 (MT Newswires) -- HomeStreet ( HMST ) said Tuesday it received shareholder approval Tuesday for its merger with FirstSun Capital Bancorp and Dynamis Subsidiary. HomeStreet ( HMST ) said closing of the merger is still subject to receipt of the required regulatory approvals. Price: 10.24, Change: -0.26, Percent Change: -2.48 ...

NeueHealth Gets NYSE Noncompliance Notice Over Market Cap Requirements

Jun 18, 2024

05:31 PM EDT, 06/18/2024 (MT Newswires) -- NeueHealth ( NEUE ) said late Tuesday the New York Stock Exchange notified the company June 12 of its noncompliance with the exchange's requirements for continued listing. The NYSE said the company's average market capitalization over a consecutive 30 trading-day period was below $50 million and its last reported stockholders' equity was less...

Apple turns to third parties for 'buy now, pay later' after sunsetting product

Jun 18, 2024

(Reuters) - Although Apple is discontinuing its buy now, pay later service launched last year, the company is sticking with the product, with a successor to the offering launching later this year via third-parties like Affirm. Buy now, pay later (BNPL) exploded in popularity as the COVID-19 pandemic forced more shoppers online, and the product has continued to resonate with...

Century Therapeutics Proposes Secondary Offering of 7.87 Million Shares

Jun 18, 2024

05:40 PM EDT, 06/18/2024 (MT Newswires) -- Century Therapeutics ( IPSC ) proposed a secondary stock offering of 7.87 million shares. The company said Tuesday in a regulatory filing it won't sell stock in the proposed sale for selling shareholders or get any of the proceeds Shares of the company rose 4.7% in recent after-hours activity. Price: 3.1100, Change: +0.14,...